GlassScriptPhysician profile
Edward R Kessler
NPI 1427205699
$15,341.95
in general payments reported to CMS, 2019-2025
32 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,114 · 2020: $1,539 · 2021: $1,672 · 2022: $5,488 · 2023: $197 · 2024: $2,194 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $529.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,317.86 | 2019-2024 | Da Vinci Surgical System |
| Veran Medical Technologies, INC. | $1,842.05 | 2019-2020 | |
| Pulmonx Corporation | $1,291.07 | 2019 | |
| Glaxosmithkline, LLC. | $1,242.74 | 2019-2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $918.46 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $809.80 | 2019-2023 | Ofev |
| Grifols USA, LLC | $787.28 | 2019-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $396.39 | 2019-2021 | |
| Harmony Biosciences LLC | $189.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.03 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $162.15 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $150.55 | 2019-2022 | |
| Philips North America LLC | $149.87 | 2019-2024 | (Ak6) Vest Therapy |
| Bayer Healthcare Pharmaceuticals INC. | $134.95 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $104.89 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $93.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $91.93 | 2019-2022 | |
| Amgen INC. | $62.13 | 2022 | |
| Ethicon INC. | $55.50 | 2021 | |
| United Therapeutics Corporation | $51.75 | 2021 | |
| Advanced Respiratory, INC | $44.01 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $41.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $39.92 | 2019-2021 | |
| Verona Pharma, INC. | $36.99 | 2025 | Ohtuvayre |
| Vapotherm INC | $24.75 | 2022 | |
| Genentech USA, INC. | $22.06 | 2019 | |
| Baxter Healthcare | $21.45 | 2022 | |
| Eisai INC. | $19.31 | 2021 | |
| Novo Nordisk INC | $17.78 | 2022 | |
| Covidien LP | $16.86 | 2019 | |
| Bard Peripheral Vascular, INC. | $15.95 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.